Testing effectiveness (Phase 2)Ended earlyNCT04402008What this trial is testingStudy of Poziotinib in Japanese Patients With NSCLCWho this might be right forNSCLC Spectrum Pharmaceuticals, Inc 42
Not applicableAvailableNCT07601399What this trial is testingAn EAP Treatment Protocol of ZipalertinibWho this might be right forNon-Small Cell Lung Cancer Taiho Oncology, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06192849What this trial is testingTo Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant ChemotherapyWho this might be right forNon Small Cell Lung CancerEGFR Exon 20 Insertion Mutation Juan LI, MD 20
Testing effectiveness (Phase 2)UnknownNCT04974879What this trial is testingOsimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung CancerWho this might be right forCarcinoma, Non-Small-Cell Lung Qingdao Central Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT06043817What this trial is testingFirst-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion MutationsWho this might be right forNon-Small Cell Lung CancerNSCLCEGFR/HER2 Exon 20 Insertion Mutation Pierre Fabre Medicament 345
Early research (Phase 1)Ended earlyNCT05241873What this trial is testing(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsWho this might be right forLung Neoplasm MalignantCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+17 more Blueprint Medicines Corporation 103
Testing effectiveness (Phase 2)UnknownNCT05132777What this trial is testingEfficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung CancerWho this might be right forLocally Advanced or Metastatic Non-Small Cell Lung CancerEGFR Exon20 Insertion Mutations Shanghai JMT-Bio Inc. 155
Testing effectiveness (Phase 2)Ended earlyNCT03744715What this trial is testingAllow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to PoziotinibWho this might be right forNSCLCBreast Cancer Spectrum Pharmaceuticals, Inc 7
Not applicableLooking for participantsNCT06247826What this trial is testingMechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 InsertionWho this might be right forNon-small Cell Lung CancerEGFR Exon 20 Insertion Mutation Groupe Francais De Pneumo-Cancerologie 30
Not applicableWithdrawnNCT05863819What this trial is testingA Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)Who this might be right forNon-small Cell Lung Cancer (NSCLC) Takeda
Testing effectiveness (Phase 2)UnknownNCT05498389What this trial is testingEMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung CancerWho this might be right forMetastatic Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8+6 more Shanghai EpimAb Biotherapeutics Co., Ltd. 115
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07229339What this trial is testingZipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung CancerWho this might be right forLung Non-Squamous Non-Small Cell Carcinoma Jonsson Comprehensive Cancer Center 16
Testing effectiveness (Phase 2)Ended earlyNCT03318939What this trial is testingPhase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationWho this might be right forNSCLC Spectrum Pharmaceuticals, Inc 648
Testing effectiveness (Phase 2)Active Not RecruitingNCT05466149What this trial is testingEfficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 InsertionWho this might be right forNSCLC Allist Pharmaceuticals, Inc. 100
Not applicableStudy completedNCT05419700What this trial is testingA Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 InsertionWho this might be right forNon-small Cell Lung Cancer (NSCLC) Takeda 76
Not applicableLooking for participantsNCT06418412What this trial is testingA Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLCWho this might be right forAdvanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer National Cancer Centre, Singapore 600
Early research (Phase 1)Study completedNCT06001671What this trial is testingAntitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLCWho this might be right forNSCLC Hunan Province Tumor Hospital 23
Testing effectiveness (Phase 2)Looking for participantsNCT06616766What this trial is testingA Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946Who this might be right forNSCLC (Non-small Cell Lung Cancer)Solid Tumor Yuhan Corporation 201
Testing effectiveness (Phase 2)UnknownNCT04063462What this trial is testingPhase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion MutationWho this might be right forNon Small Cell Lung Cancer Tianjin Medical University Cancer Institute and Hospital 60
Large-scale testing (Phase 3)Active Not RecruitingNCT05668988What this trial is testingDZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Who this might be right forNon-small Cell Lung Cancer Dizal Pharmaceuticals 324